In patients with BSI, antiplatelet therapy significantly reduced 30-day all-cause mortality without an increasing risk of bleeding.
Sun et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: